Momentum on Two Fronts for Rejuvenation

This month has been marked by progress in both the regulatory and investment sides of rejuvenation biotechnology. For years, the field has faced two major challenges: scientific advances outpacing the regulatory systems meant to evaluate them, and a capital environment that has often struggled to distinguish serious translational work from noise and hype.

Fortunately, recent developments suggest that both fronts are shifting, signaling that our field has entered a more mature phase.

A regulatory shift towards biomedical repair

The most significant signal came from the FDA itself. At the recent Aging Research and Drug Discovery (ARDD) meeting in Boston, senior agency leaders publicly named longevity a priority and suggested that regulatory science is beginning to engage with the unique features of aging biology.

Our coverage of that panel, FDA Leaders Name Longevity a Priority at ARDD, reported a notable change in tone. The discussion did not focus on declaring aging a disease; it was about recognizing that interventions that target the biology of aging need fit-for-purpose endpoints, platform-based approaches, and clearer development pathways.

We have long argued at LRI that the debate over whether aging is or is not a disease is largely a distraction. Harvard Medical School researcher Vadim Gladyshev has framed the issue more usefully: aging is neither a classic disease nor a non-disease, but the cumulative biological backdrop against which age-related pathology emerges. The more productive question is not “Is aging a disease?” but “How can we design regulatory pathways that can evaluate interventions targeting that underlying biology?”

This is the direct backdrop for our recent whitepaper The Regulatory Bottleneck in Aging Biology: Why Platform Designations and Surrogate Endpoints Matter Now, which was published recently. Our paper proposes that the barrier to progress is increasingly institutional rather than purely biological.

Platform technology designations, validated surrogate endpoints, and iterative development models already exist in other therapeutic areas. Extending them to encompass multiple-disease or hallmark-based therapies is one of the best ways to leverage single-organ advances into broader health and economic benefits.

The whitepaper is written for policymakers, regulators, and funders who need a clear, evidence-based case for supporting biomedical repair therapies. It serves as a case for modernization of the regulatory framework and makes recommendations on how this could be achieved.

Achieving the Longevity Dividend

Complementing the regulatory analysis is our recent piece Why Democratizing Rejuvenation Is an Economic Imperative. If effective biomedical repair technologies remain accessible only to a narrow segment of the population, the economic and social costs will be substantial. The opposite is far more desirable from both an economic and social point of view and would help us to achieve what economists term the Longevity Dividend.

The article makes the case that equitable access is not merely a fairness issue; it is a fiscal and productivity one. The Longevity Dividend can only be achieved if biomedical repair therapies are made widely accessible as they become available.

First human trial data for partial cellular reprogramming

Meanwhile, Life Biosciences has announced the first human data from its partial reprogramming clinical trial. ER-100, an OSK gene therapy delivered to the eye, reported interim Phase 1 results showing that the low dose was well tolerated in three glaucoma patients, with preliminary visual field signals in two of the three.

It must be stressed that this is early and limited data, but it is the kind of concrete clinical step that the field needs to progress. This is distinct from unpublished research cocktails being made into supplements that remain outside regulatory pathways.

An economic shift towards longer healthy lives

A quieter but telling external signal appeared in mainstream investing media. In a recent Investing Unlocked discussion titled Is Longevity the Next Big Investment Boom?, Georgie Frost and Maike Currie were joined by David Sinclair (Chief Executive of the International Longevity Centre, not the Harvard geneticist) to examine what longer lives and falling birth rates mean for investors.

The discussion focused on pensions, productivity, and the “silver economy” rather than speculative biotech stories. While this might appear modest at first glance, the framing is significant.

When ordinary financial analysis starts treating extended healthy life as a variable that must be priced into markets and policy, it indicates the topic is moving out of the fringe and into institutional thinking. This is one example of the capital counterpart to the regulatory shift we are also seeing.

Where the money meets the science

Meanwhile at LRI, the practical work of connecting serious science with investors continues through our Longevity Investor Network program.

With this in mind, we are holding two focused industry events this season:

Longevity Biotech Pitch Night in New York

Hosted by the Longevity Investor Network & Lifespan Research Institute

​When: Thursday, November 19, 2026

Where: New York City

Longevity Biotech Pitch Day in San Francisco during JPM week

Hosted by the Longevity Investor Network & Lifespan Research Institute

​When: Thursday, January 9, 2027

Where: San Francisco Bay Area

We started the Longevity Investors Network when longevity was still seen as fringe science. We believed in the science and the future of this emerging field. Our goal was to help the founders building this field find the capital and support they needed. Now, the world is finally catching up.

— Javier Noris, Longevity Investor Network Managing Director

Both events are designed to give high-quality companies direct access to investors who understand the difference between hype and translational progress. Capital allocation still decides which programs move forward and which stall. We’ve always seen our role as helping the ecosystem to grow, these gatherings are one of the ways we are continuing to do our part.

If you are interested in presenting your company or being a sponsor at either of these events, please contact Javier Noris to discuss.

What does this mean for longevity?

Taken together, the picture is clear. Regulatory attention is sharpening, the economic case for broad access is being articulated more clearly, and mainstream capital is beginning to treat longer healthy life as a realistic goal rather than a speculative curiosity.

Of course, none of this guarantees rapid success because the biology remains complex and the timeline is still measured in years. However, the institutional framework required to make meaningful progress is becoming more visible. That is the situation as it stands, and we will continue to support all efforts to make longer, healthier lives a reality.